Chromadex Corp reports results for the quarter ended in March - Earnings Summary

Niagen Bioscience

10/05/2023 22:03

* Chromadex Corp  CDXC.OQ  reported a quarterly adjusted
loss of 3
cents​​ per share for the quarter ended in March. The mean
expectation of five analysts for the quarter was for a loss of 5
cents per share.
    * Revenue rose 30.7% to $22.56 million from a year ago;
analysts
expected $19.32 million. 
    * Chromadex Corp's reported EPS for the quarter was a loss
of 3
cents​.
    * The mean earnings estimate of analysts had fallen by
about 92%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Chromadex Corp shares had fallen by 9.5% this quarter and
lost 17.6% so far this year.
    * The company reported a quarterly loss of $1.9 million.
    * Wall Street's median 12-month price target for Chromadex
Corp is
$5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
10 at 09:03 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.05          -0.03          Beat
 Dec. 31 2022      -0.02          -0.02          Met
 Sep. 30 2022      -0.06          -0.04          Beat
 Jun. 30 2022      -0.08          -0.09          Missed